Dr. Borgen on the Decision to be Tested for a BRCA Gene
Patrick Borgen, MD
Published Online: Thursday, May 23, 2013
Patrick Borgen, MD, chair, Department of Surgery, director, Maimonides Breast Cancer Center, discusses a patient's decision to be tested for a BRCA gene.
Borgen says that testing for a BRCA gene can have profound impact on individuals and families and that the decision to be tested should remain up to the patient.
While few women regret having a prophylactic or risk-reducing mastectomy, some do. These women who regret the procedure, Borgen says, are often those who are talked into it by their physician. The physician's job is to inform a patient about the costs and benefits of the procedure and let them make the decision.
The most promising novel therapeutics in development for patients with breast cancer focus primarily on targeting activating mutations in combinations that are based on findings from next-generation sequencing.
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses using adjuvant bisphosphonates as a treatment option for patients with breast cancer.
Judy C. Boughey, MD, associate professor of surgery, director, Breast Surgical Oncology Training Program, Mayo Clinic, discusses surgical resection of the primary breast tumor in patients with stage IV breast cancer.